Press Release

MONTREAL, April 3, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that new additional follow-up data from its latest NAP-based combination trials in HBV infection (REP 401 study) and HBV / HDV co-infection (REP 301-LTF study) will be presented at the 2018 International Liver Conference (ILC) hosted by the European Society for the Study of the Liver (EASL) to be held April 11-15, 2018 in Paris, France.

The REP 401 study (NCT02565719) is a randomized, controlled trial assessing the safety and efficacy of Replicor’s lead HBsAg release inhibitor, REP 2139-Mg and of a REP 2139 derivative with enhanced plasma and tissue clearance (REP 2165-Mg) in combination with tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha 2a (peg-IFN) in 40 patients with chronic HBeAg negative HBV infection. Poster FRI-343 will feature further extended follow-up in patients in the experimental arm as well as new follow up data from patients in the adaptive control arm (who crossed over to experimental therapy in the absence of a HBsAg response during TDF and pegIFN).

The REP 301-LTF study (NCT02876419) provides a long term follow-up on patients with chronic HBV / HDV co-infection completing combination therapy with REP 2139-Ca and pegIFN in the REP 301 study (NCT02233075). Poster FRI-326 (also featured during the HDV oral e-poster session on Saturday) will include follow-up data now extended to 1.5-2 years.

Updated modelling of viral kinetics during REP 2139-Ca monotherapy in HBeAg+ chronic HBV infection in the REP 102 study (NCT02646189) will also be featured in Poster FRI-324.

Replicor’s presentations from EASL ILC 2018 will be available on the company’s website following their disclosure at the meeting at For further information about the EASL ILC 2018 visit:

About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at

Media Contact:
Natacha Dorget
(514) 733-1998